Press Releases

Trial Data Expected to Provide Further Clinical Validation of Biocept's CTC and ctDNA Liquid Biopsy Testing and Platforms for Biomarker Detection in Patients Diagnosed with Non-Small Cell Lung Cancer

Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic SAN DIEGO , April 9, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide

Study results to be presented at the Fifth AACR-IASLC International Joint Conference

Key Microfluidic Channel Patent Granted to Biocept in Europe

Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota   SAN DIEGO (December 18, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide

SAN DIEGO --(BUSINESS WIRE)--Sep. 8, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the

Increases coverage to approximately 31 million PPO members SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces additional agreements with

Increases patient in-network coverage to approximately 133 million PPO consumers

Increases coverage to approximately 140 million PPO consumers

More than 40 million Americans gain access to Biocept's liquid biopsy tests through the FedMed National Provider NetworkBiocept increases coverage to more than 180 million PPO consumers